Key Disease Mechanisms Linked to Amyotrophic Lateral Sclerosis in Spinal Cord Motor Neurons
暂无分享,去创建一个
[1] Yong-jie Wei,et al. Risk of neurodegeneration among residents of electronic waste recycling areas. , 2021, Ecotoxicology and environmental safety.
[2] A. Soricelli,et al. Machine Learning and Bioinformatics Framework Integration to Potential Familial DCM-Related Markers Discovery , 2021, Genes.
[3] L. Wong,et al. Epigenetics Modifications in Large-Artery Atherosclerosis: A Systematic Review. , 2021, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[4] J. Matías‐Guiu,et al. A Transcriptomic Meta-Analysis Shows Lipid Metabolism Dysregulation as an Early Pathological Mechanism in the Spinal Cord of SOD1 Mice , 2021, International journal of molecular sciences.
[5] Shi-Yan Ng,et al. TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination , 2021, The Journal of cell biology.
[6] Hui Zhou,et al. Benzo(a)pyrene exposure in utero exacerbates Parkinson's Disease (PD)-like α-synucleinopathy in A53T human alpha-synuclein transgenic mice. , 2021, Toxicology and applied pharmacology.
[7] Jose A. Santiago,et al. Network Analysis Identifies Sex-Specific Gene Expression Changes in Blood of Amyotrophic Lateral Sclerosis Patients , 2021, International journal of molecular sciences.
[8] M. Onofrj,et al. Diabetes Mellitus and Amyotrophic Lateral Sclerosis: A Systematic Review , 2021, Biomolecules.
[9] J. W. Joo,et al. An Integrative Transcriptome-Wide Analysis of Amyotrophic Lateral Sclerosis for the Identification of Potential Genetic Markers and Drug Candidates , 2021, International journal of molecular sciences.
[10] Baoman Li,et al. Astrocytes in heavy metal neurotoxicity and neurodegeneration , 2021, Brain Research.
[11] Weineng Chen,et al. Key Molecules and Pathways Underlying Sporadic Amyotrophic Lateral Sclerosis: Integrated Analysis on Gene Expression Profiles of Motor Neurons , 2020, Frontiers in Genetics.
[12] P. Ungprasert,et al. Diabetes mellitus is associated with a lower risk of amyotrophic lateral sclerosis: A systematic review and meta-analysis , 2020, Clinical Neurology and Neurosurgery.
[13] N. Wray,et al. Cardiovascular disease, psychiatric diagnosis and sex differences in the multistep hypothesis of amyotrophic lateral sclerosis , 2020, European journal of neurology.
[14] M. Chang,et al. The effectiveness of nonsteroidal anti-inflammatory drugs and acetaminophen in reduce the risk of amyotrophic lateral sclerosis? A meta-analysis , 2020, Scientific Reports.
[15] J. Sterneckert,et al. Genome Wide Analysis Points towards Subtype-Specific Diseases in Different Genetic Forms of Amyotrophic Lateral Sclerosis , 2020, International journal of molecular sciences.
[16] Yinxi Wang,et al. Benzo(a)pyrene exposure induced neuronal loss, plaque deposition, and cognitive decline in APP/PS1 mice , 2020, Journal of Neuroinflammation.
[17] Ashwini Kumar,et al. Minutes of PPAR-γ agonism and neuroprotection , 2020, Neurochemistry International.
[18] Shijie Jin,et al. Elevated exosomal secretion of miR-124-3p from spinal neurons positively associates with disease severity in ALS , 2020, Experimental Neurology.
[19] E. D’Amico,et al. CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. , 2020, Environmental research.
[20] Jose A. Santiago,et al. Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene , 2020, International journal of molecular sciences.
[21] S. Deep,et al. Quercetin and baicalein act as a potent anti-amyloidogenic and fibril destabilizing agents for SOD1 fibrils. , 2020, ACS chemical neuroscience.
[22] M. Turner,et al. Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis , 2020, Brain communications.
[23] A. Rodal,et al. TDP-43 dysfunction restricts dendritic complexity by inhibiting CREB activation and altering gene expression , 2019, Proceedings of the National Academy of Sciences.
[24] Phillip A. Richmond,et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles , 2019, Nucleic Acids Res..
[25] Julian M. W. Quinn,et al. Identification of molecular signatures and pathways to identify novel therapeutic targets in Alzheimer's disease: Insights from a systems biomedicine perspective. , 2020, Genomics.
[26] Carbamazepine , 2019, Reactions Weekly.
[27] E. Fraenkel,et al. Early epigenomic and transcriptional changes reveal Elk-1 transcription factor as a therapeutic target in Huntington’s disease , 2019, Proceedings of the National Academy of Sciences.
[28] Jose A. Santiago,et al. Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer’s patients , 2019, PloS one.
[29] Ching-On Wong,et al. Motor neurons from ALS patients with mutations in C9ORF72 and SOD1 exhibit distinct transcriptional landscapes. , 2019, Human molecular genetics.
[30] Chen Peng,et al. Epigenome-Wide Association Study Indicates Hypomethylation of MTRNR2L8 in Large-Artery Atherosclerosis Stroke. , 2019, Stroke.
[31] Othman Soufan,et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis , 2019, Nucleic Acids Res..
[32] Mohammad Ali Moni,et al. Network-based approach to identify molecular signatures and therapeutic agents in Alzheimer's disease , 2019, Comput. Biol. Chem..
[33] Nick C Fox,et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.
[34] W. Le,et al. Repurposing carbamazepine for the treatment of amyotrophic lateral sclerosis in SOD1‐G93A mouse model , 2018, CNS neuroscience & therapeutics.
[35] J. Fernández-Ruiz,et al. Neuroprotective effects of the cannabigerol quinone derivative VCE‐003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis , 2018, Biochemical pharmacology.
[36] Federica Conte,et al. Network-Based Approaches to Explore Complex Biological Systems towards Network Medicine , 2018, Genes.
[37] I. Simone,et al. Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis , 2018, Front. Mol. Neurosci..
[38] C. Serra,et al. Disruption by SaCas9 Endonuclease of HERV-Kenv, a Retroviral Gene with Oncogenic and Neuropathogenic Potential, Inhibits Molecules Involved in Cancer and Amyotrophic Lateral Sclerosis , 2018, Viruses.
[39] P. Andersen,et al. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion , 2018, Annals of neurology.
[40] F. Zhou,et al. Raloxifene, a promising estrogen replacement, limits TDP-25 cell death by enhancing autophagy and suppressing apoptosis , 2018, Brain Research Bulletin.
[41] Satoshi O. Suzuki,et al. Expression of CRYM in different rat organs during development and its decreased expression in degenerating pyramidal tracts in amyotrophic lateral sclerosis , 2018, Neuropathology : official journal of the Japanese Society of Neuropathology.
[42] Yasuo Watanabe,et al. Edaravone and cyclosporine A as neuroprotective agents for acute ischemic stroke , 2018, Acute medicine & surgery.
[43] M. Alarcón,et al. New insights into the gene expression associated to amyotrophic lateral sclerosis. , 2018, Life sciences.
[44] A. Chiò,et al. The role of pre‐morbid diabetes on developing amyotrophic lateral sclerosis , 2018, European journal of neurology.
[45] Artemis G. Hatzigeorgiou,et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions , 2017, Nucleic Acids Res..
[46] Hsien-Da Huang,et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions , 2017, Nucleic Acids Res..
[47] Stephen A. Goutman,et al. Amyotrophic lateral sclerosis , 2022, Nature Reviews Disease Primers.
[48] Daniela A. Recabarren,et al. Gene networks in neurodegenerative disorders. , 2017, Life sciences.
[49] J. Kira,et al. Differential activation of neuronal and glial STAT3 in the spinal cord of the SOD1G93A mouse model of amyotrophic lateral sclerosis , 2017, The European journal of neuroscience.
[50] Vijay Pande,et al. Quercitrin and quercetin 3-&bgr;-D-glucoside as chemical chaperones for the A4V SOD1 ALS-causing mutant , 2017, Protein engineering, design & selection : PEDS.
[51] Hongquan Jiang,et al. Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid , 2016, International journal of molecular sciences.
[52] M. Weisskopf,et al. Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: A population based study , 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[53] R. Sharma,et al. Quercetin attenuates neuronal death against aluminum-induced neurodegeneration in the rat hippocampus , 2016, Neuroscience.
[54] N. Mewton,et al. Cyclosporine A, a Potential Therapy of Ischemic Reperfusion Injury. A Common History for Heart and Brain , 2016, Cerebrovascular Diseases.
[55] S. Schmidt,et al. Blood levels of trace metals and amyotrophic lateral sclerosis. , 2016, Neurotoxicology.
[56] Fabian J Theis,et al. miTALOS v2: Analyzing Tissue Specific microRNA Function , 2016, PloS one.
[57] Hsien-Da Huang,et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..
[58] P. Preux,et al. Epidemiology of amyotrophic lateral sclerosis: A review of literature. , 2016, Revue neurologique.
[59] A. Taraszewska,et al. Protective effect of valproic acid on cultured motor neurons under glutamate excitotoxic conditions. Ultrastructural study. , 2015, Folia neuropathologica.
[60] Y. Bossé,et al. Altered intestinal functions and increased local inflammation in insulin-resistant obese subjects: a gene-expression profile analysis , 2015, BMC Gastroenterology.
[61] D. Chuang,et al. Downregulated AEG-1 together with inhibited PI3K/Akt pathway is associated with reduced viability of motor neurons in an ALS model , 2015, Molecular and Cellular Neuroscience.
[62] M. Ren,et al. Notch pathway is activated in cell culture and mouse models of mutant SOD1-related familial amyotrophic lateral sclerosis, with suppression of its activation as an additional mechanism of neuroprotection for lithium and valproate , 2015, Neuroscience.
[63] M. Weisskopf,et al. Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study. , 2015, JAMA neurology.
[64] M. Rattray,et al. C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis , 2015, PloS one.
[65] Xuebing Ding,et al. Valproate Attenuates 25-kDa C-Terminal Fragment of TDP-43-Induced Neuronal Toxicity via Suppressing Endoplasmic Reticulum Stress and Activating Autophagy , 2015, International journal of biological sciences.
[66] M. Fehlings,et al. Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside , 2015, Molecules.
[67] Daniela C. Zarnescu,et al. PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. , 2015, Human molecular genetics.
[68] F. Piehl,et al. Risk factors for amyotrophic lateral sclerosis , 2015, Clinical epidemiology.
[69] N. Pochet,et al. Targeting miR‐155 restores abnormal microglia and attenuates disease in SOD1 mice , 2015, Annals of neurology.
[70] Samira N. Kashefi,et al. Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study , 2015, Journal of Neural Transmission.
[71] R. Bullock,et al. Evidence to support mitochondrial neuroprotection, in severe traumatic brain injury , 2015, Journal of Bioenergetics and Biomembranes.
[72] Johnathan Cooper-Knock,et al. Loss of nuclear TDP‐43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones , 2014, Neuropathology and applied neurobiology.
[73] H. Akiyama,et al. Distinct pathways leading to TDP-43-induced cellular dysfunctions. , 2014, Human molecular genetics.
[74] Junling Gao,et al. STAT3 Modulation to Enhance Motor Neuron Differentiation in Human Neural Stem Cells , 2014, PloS one.
[75] C. Ríos,et al. Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis , 2014, Journal of the Neurological Sciences.
[76] Rui Huang,et al. An exploratory study of the association between thyroid hormone and survival of amyotrophic lateral sclerosis , 2014, Neurological Sciences.
[77] Hanfei Sun,et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA , 2013, Nature Protocols.
[78] G. Olmos,et al. Neuroprotective Effects of Estradiol on Motoneurons in a Model of Rat Spinal Cord Embryonic Explants , 2013, Cellular and Molecular Neurobiology.
[79] S. Booth,et al. Early Mechanisms of Pathobiology Are Revealed by Transcriptional Temporal Dynamics in Hippocampal CA1 Neurons of Prion Infected Mice , 2012, PLoS pathogens.
[80] Gerry Shaw,et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[81] A. Maggi,et al. The Peroxisome Proliferator-activated Receptor γ (PPARγ) Controls Natural Protective Mechanisms against Lipid Peroxidation in Amyotrophic Lateral Sclerosis , 2012, The Journal of Biological Chemistry.
[82] Samira N. Kashefi,et al. Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study , 2012, Acta Neuropathologica.
[83] U. Bogdahn,et al. A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis , 2012, PloS one.
[84] S. Rutkove,et al. Reducing systemic hypermetabolism by inducing hypothyroidism does not prolong survival in the SOD1-G93A mouse , 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[85] A. Giralt,et al. Activation of Elk‐1 participates as a neuroprotective compensatory mechanism in models of Huntington’s disease , 2012, Journal of neurochemistry.
[86] Xiaozhong Peng,et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice , 2012, Neurobiology of Aging.
[87] S. Johann,et al. Regulation of Choline Acetyltransferase Expression by 17β‐Oestradiol in NSC‐34 Cells and in the Spinal Cord , 2011, Journal of neuroendocrinology.
[88] Fabian J Theis,et al. miTALOS: analyzing the tissue-specific regulation of signaling pathways by human and mouse microRNAs. , 2011, RNA.
[89] L. Garcia-Segura,et al. Selective estrogen receptor modulators as brain therapeutic agents. , 2011, Journal of molecular endocrinology.
[90] B. Sharrack,et al. Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis , 2011, Brain : a journal of neurology.
[91] Pamela A McCombe,et al. Effects of gender in amyotrophic lateral sclerosis. , 2010, Gender medicine.
[92] J. Ávila. Common mechanisms in neurodegeneration , 2010, Nature Medicine.
[93] Avi Ma'ayan,et al. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments , 2010, Bioinform..
[94] K. Gruis,et al. The Association of Exposure to Lead, Mercury, and Selenium and the Development of Amyotrophic Lateral Sclerosis and the Epigenetic Implications , 2010, Neurodegenerative Diseases.
[95] Paul G. Ince,et al. Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS) , 2010, PloS one.
[96] J. Eberwine,et al. A Neurotoxic Phosphoform of Elk-1 Associates with Inclusions from Multiple Neurodegenerative Diseases , 2010, PloS one.
[97] A. Hiroi,et al. Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1‐mutated amyotrophic lateral sclerosis , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.
[98] A. Higginbottom,et al. Mutations in CHMP 2 B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis ( ALS ) , 2010 .
[99] L. H. van den Berg,et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis , 2009, Annals of neurology.
[100] A. Kakita,et al. Activation of Signal Transducer and Activator of Transcription-3 in the Spinal Cord of Sporadic Amyotrophic Lateral Sclerosis Patients , 2009, Neurodegenerative Diseases.
[101] A. Contestabile,et al. Long‐term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis , 2009, Muscle & nerve.
[102] D. Chuang,et al. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model , 2008, Neuroscience.
[103] B. Gwag,et al. Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice , 2008, Journal of the Neurological Sciences.
[104] M. Kiaei. Peroxisome Proliferator-Activated Receptor-γ in Amyotrophic Lateral Sclerosis and Huntington's Disease , 2008, PPAR research.
[105] Robert H. Brown,et al. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[106] A. Echaniz-Laguna,et al. Sodium Valproate Exerts Neuroprotective Effects In Vivo through CREB-Binding Protein-Dependent Mechanisms But Does Not Improve Survival in an Amyotrophic Lateral Sclerosis Mouse Model , 2007, The Journal of Neuroscience.
[107] N. Howell,et al. Development of 17α‐Estradiol as a Neuroprotective Therapeutic Agent: Rationale and Results from a Phase I Clinical Study , 2005, Annals of the New York Academy of Sciences.
[108] M. Beal,et al. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis , 2005, Experimental Neurology.
[109] S. Sakoda,et al. Benefit of valproic acid in suppressing disease progression of ALS model mice , 2004, The European journal of neuroscience.
[110] L. V. D. Berg,et al. Ovariectomy and 17beta-estradiol modulate disease progression of a mouse model of ALS. , 2004, Brain research.
[111] W. Bradley,et al. An ALS mouse model with a permeable blood–brain barrier benefits from systemic cyclosporine A treatment , 2004, Journal of neurochemistry.
[112] G. Stephanopoulos,et al. Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. , 2004, Physiological genomics.
[113] C. Mattingly,et al. The Comparative Toxicogenomics Database (CTD). , 2003, Environmental health perspectives.
[114] K. Csiszȧr,et al. Intrathecal cyclosporin prolongs survival of late-stage ALS mice , 2001, Brain Research.
[115] S. Shimohama,et al. Protection of cultured spinal motor neurons by estradiol , 2000, Neuroreport.
[116] S. Heck,et al. The female sex hormone oestrogen as neuroprotectant: activities at various levels. , 2000, Novartis Foundation symposium.
[117] Susumu Goto,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..
[118] S H Appel,et al. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. , 1995, Brain : a journal of neurology.